Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant

Sponsor
Zhejiang University
Study ID
NCT04035876
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

To assess the primary effects and safety of camrelizumab (SHR-1210) plus apatinib for downstaging/bridging of HCC before liver transplantation.

Key Dates

Start date
Jul 16, 2019
Status verified
Jul 2019
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021

Study Design

Enrollment
120 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab plus apatinib

Primary Outcome Measure

Objective remission rate [ Time Frame: From enrollment to disease progression, up to 6 months ]

Central Contacts

Related Studies